Biogen Idec News

WATERTOWN, Mass. -- -- EnVivo Pharmaceuticals , a company dedicated to developing a broad range of novel central nervous system therapies, today announced the appointment of Alfred Sandrock, M.D., Ph.D., to the company's board of directors .

WESTON, Mass. & DUBLIN -- -- Biogen Idec and Elan Corporation , plc today announced that the New England Journal of Medicine published research from the companies' global risk management program that updates the risk of TYSABRI -associated progressive multifocal leukoencephalopathy , an infrequent but serious brain infection that usually leads to ... (more)

WEDNESDAY, May 16 -- Drug company researchers say they've determined which multiple sclerosis patients are most vulnerable to developing a rare brain infection while taking a powerful drug called Tysabri .

American Dg Energy : A subsidiary of American DG Energy, EuroSite Power, has entered into an agreement with Abbeycroft Leisure to provide clean energy, heating and cooling to Suffolk's Haverhill Leisure Centre.

Samsung Bioepis is a joint venture between Samsung Biologics and Biogen Idec to develop, manufacture, and market biosimilars.

Biogen Idec announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX for relapsing forms of multiple sclerosis are now available in U.S. pharmacies:     The new AVONEX PEN is the first intramuscular autoinjector for chronic use, designed to enhance the self-injection process for patients ... (more)

's stock had its "buy" rating reaffirmed by research analysts at Goldman Sachs in a report released on Thursday.

WESTON, Mass. -- -- Today Biogen Idec announced that U.S. and EU regulatory authorities have accepted the company's marketing applications for the review of BG-12 , an oral therapeutic candidate for the treatment of multiple sclerosis .

The firm currently has a "buy" rating on the stock. A number of other analysts have also recently weighed in on BIIB.

WESTON, Mass. -- -- Biogen Idec Inc. announced today that its presentation at the Deutsche Bank 37th Annual Healthcare Conference will be webcast live on Tuesday, May 8, 2012 at 10:00 a.m. ET.

Biogen Idec Inc : Based upon data available to us through the TOUCH prescribing program and other third-party sources, as of the end of March 2012, we estimate that approximately 66,600 patients were on commercial and clinical TYSABRI therapy worldwide, and that cumulatively approximately 99,600 patients have ever been treated with TYSABRI in the ... (more)

's stock had its "neutral" rating reiterated by equities research analysts at Robert W. Baird in a research note issued to investors on Tuesday.

Shareholder Representative Services' latest Q&A features Michael Gilman. Gilman led Stromedix to an acquisition by Biogen Idec valued at up to $562.5 million.

Good morning. My name is Melissa, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Idec First Quarter 2012 Earnings Conference Call.

WESTON, Mass.-- --May 1, 2012 - Biogen Idec Inc. , a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.

Pfizer, Inc. will unveil its latest earnings on Tuesday, May 1, 2012. The average analyst estimate is for profit of 56 cents per share, a decline of 6.7% from the company's actual earnings for the year-ago quarter.

Pfizer : The whisper number is $0.57, one cent ahead of the analysts estimate. Pfizer has a 58% positive surprise history .

Both calls and puts are trading at five times their respective intraday volumes.

A number of other firms have also recently commented on BIIB. Analysts at Oppenheimer raised their price target on shares of Biogen Idec from $127.00 to $136.00 in a research note to investors on Wednesday, April 25th.